Abbott research business spin off steers clear of Pill Hill operations
A corporate shuffle at the global drug maker will not impact the company’s Mississauga diabetes and diagnostic tests division
Author: Karen K. Ho
I'm a global economics and finance reporter at Quartz based in New York.
Square One retailers failing to comply with privacy laws
A UofT study has found most of the stores at the shopping centre do not have proper signage about video cameras
Drug research companies could benefit from new patent rules, says industry group
As Mississauga’s drug research companies prepare for possible new patent rules under the Canada-EU free trade deal, an industry group says improved intellectual property protection would be a shot in the arm for the city’s pivotal life sciences sector
Brampton’s Organic Oven bakes up sweet allergy-free treats
A Brampton bakery is making sure there are plenty of baked goods, from pies to cupcakes, for celiacs and gluten-sensitive customers can enjoy
Demand for gluten-free prompts new restaurants and more food options
More restaurants and stores are introducing gluten-free options and products in response to increased awareness of the growing number of Canadians with celiac disease or gluten sensitivity
Recruiter says Takhar’s employment agency crackdown will hurt legit operations
Local recruitment firm says Liberal leadership candidate’s proposal for stricter regulation to keep temporary workers from being exploited by work placement agencies will be hard on reputable businesses
Chemi Pharmaceutical clients visiting lab following licence suspension
Mississauga lab operator is working to assure remaining clients it is addressing issues which lead to Health Canada sanctions
Council approves business association to put Malton ‘back on the map’
The Mississauga neighbourhood of Malton received approval from city council for its own business improvement association yesterday
Mississauga Ward 5 Councillor Crombie responds to election charges
Bonnie Crombie told YourMississaugaBiz.com she expects to be cleared of 10 counts of election finance violations charged against her by a former rival
Mississauga’s YM BioSciences acquired by Gilead for $465M
Mississauga drug development company YM Biosciences announced today it had been acquired by Gilead Sciences Inc. for $465 million
Karen K. Ho 